All milestones successfully met, including antibiotic stewardship module, mobile and cloud-based data access as well as comprehensive next generation sequencing resultsTriggers additional milestone...
ROCKVILLE, Md., April 05, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that it signed an amendment to its research and development (“R&D”) collaboration agreement with FIND, to expand the collaboration which was originally started in fall of 2022. nnThe work already completed under the collaboration will be expanded by three work packages increasing total project volume to up to € 830 thousand in revenue potential. The added deliverables will address the following topics: nnAn Antimicrobial Stewardship Module supporting users with rule-based information to allow making the best treatment choices based on respective hospital’s drug availability; nA “Data everywhere” concept, investigating hardware and software options for remote connectivity in the specific environments of low- and middle- income countries (LMICs); and nNext Generation Sequencing (“NGS”) strain analysis including isolates from several sub-Saharan African countries to investigate any potential sequence differences. nDr. Gerd Luedke, Director Innovation, Technology and IP at OpGen’s German subsidiary Curetis GmbH commented: “As we approach the final milestones from the original first phase of our collaboration agreement, we are excited to expand the scope of our R&D partnership with FIND. We believe these additional steps will help us in the development of a more robust and suitable solution in LMIC countries down the road, a goal we have for the possible next phase of this collaboration under a new agreement.” nnDr. Cecilia Ferreyra, Director, FIND AMR Programme remarked that, “We look forward to seeing and evaluating the final milestone data as well as getting data from these expanded set of milestone deliverables in the coming quarter. It will help our team to better evaluate the potential of Unyvero A30 to help identify blood stream infections in patients admitted to LMIC hospitals.”